Navigation Links
Pharmaxis Long-Term Safety Study of Bronchitol Completes
Date:6/11/2008

SYDNEY, Australia, June 11 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the 12 month Phase III clinical trial evaluating the safety of Bronchitol in 100 subjects with bronchiectasis has completed.

This 12-month treatment period was an open label extension to a three- month efficacy trial which has already reported, showing that Bronchitol improved quality of life and mucus clearance. The objective of the open label extension is to determine the adverse event profile of Bronchitol following prolonged use.

Following statistical analysis, the results from this second phase of the trial will be reported in July 2008.

Pharmaxis CEO Alan Robertson said following receipt of the study report, Pharmaxis intends filing its first marketing application in Australia for Bronchitol next quarter.

''We are receiving strong demand to continue treatment after participation in the trial has concluded and, where possible, we make this available.''

Bronchitol is being developed as a twice daily inhalation therapy for people with the incurable lung condition bronchiectasis.

It is estimated that more than 600,000 people in the major pharmaceutical markets suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first targeted medication for this patient group in 20 years, addressing an important medical need. Total U.S. medical care expenditure is US$13,000 per bronchiectasis patient, double that of patients without the disorder; and an increased overall cost to the US health system of US$630 million.

Bronchiectasis is an incurable, degenerative and chronic lung condition that makes breathing difficult through excessive mucus build up in the lungs.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Reportlinker.com announces that a new ... Germany Aesthetic Lasers and Energy Devices ... http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html Germany Aesthetic Lasers and ... GlobalData,s new report, "Germany Aesthetic Lasers and ... market data on the Germany Aesthetic Lasers and ...
(Date:8/28/2014)... N.J. , Aug. 28, 2014 /PRNewswire-iReach/ -- ... medical device space, is excited to announce they ... the VIEW Plating System and REDUCE Fracture Plating ... anatomic plates used to support multiple indications within ... packaged Lapidus, First Metatarsophalangeal (MTP), Calcaneal-Cuboid (CC), Talonavicular ...
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- Academy Leadership, an elite ... graduates, has published a case study highlighting ... Excellence Course . In September and October 2014, Academy ... to Albuquerque , Indianapolis , Salt ... Photo - http://photos.prnewswire.com/prnh/20140828/140814 Leadership ...
Breaking Medicine Technology:Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9EDGE Orthopaedics Receives Second FDA Clearance 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
(Date:8/28/2014)... American adults who are beginning to ... will now have a simpler way to connect with ... this year, some of the best life insurance rates ... , The promoted plans that included price data revealed ... popular policies. The term, guaranteed and modified plans that ...
(Date:8/28/2014)... York (PRWEB) August 28, 2014 ... bellwether trial of a transvaginal mesh lawsuit ( ... Inc., Bernstein Liebhard LLP reports. Court documents pending ... West Virginia indicate that the case was filed ... undergo two revision surgeries, allegedly due to vaginal ...
(Date:8/28/2014)... Vernon, Ind. (PRWEB) August 28, 2014 ... of Valero Energy Corporation (NYSE: VLO), and the Ports ... state and local officials today at a Port Appreciation ... purchased Mount Vernon ethanol plant. , “The opening of ... Vernon is another economic development win for the ...
(Date:8/28/2014)... take wing? Did they fall from trees and learn to ... along the ground and pump their "arms" to get aloft? ... past, but a new University of California, Berkeley, study provides ... ability to maneuver in midair, a talent that could have ... a perch. , The study looked at how baby birds, ...
(Date:8/28/2014)... of Medicine published research results on Aug. 21 ... safely reduce the viral load and clinical illness of ... (RSV). , Le Bonheur Children,s Hospital and ... Disease Specialist John DeVincenzo, MD, is lead author of ... common cause of lower respiratory tract infections in young ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3Health News:DeVincenzo study breakthrough in RSV research 2
... will save lives this holiday season, NEW ... Friday" and the holiday season, New York Blood ... the children and,families whose lives are stricken by ... survival. Among these diseases are: Leukemia,and other forms ...
... efforts through second Innovation Event, INDIANAPOLIS, ... WLP ), the,nation,s largest health insurance company ... will begin accepting applications for its second ... innovation,partnership efforts by providing an accelerated process ...
... lead to vaccine that works , , THURSDAY, Nov. 13 (HealthDay ... has failed, but researchers report that they,ve still gained insight ... "It,s raised a whole new set of questions that are ... to a successful vaccine," said Dr. Susan P. Buchbinder, lead ...
... ... hospitals, ... announced HealthBIT, a healthcare business intelligence platform for,hospitals. HealthBIT(TM) provides ... and comparing their,data to provide actionable opportunities that result in ...
... shows economic,stress takes toll on the emotional and ... conducted by the American Psychological Association, shows,at least ... economy as their top,stressors. More than half, reported ... anger. Forty-six percent indicated they,were worried about providing ...
... options dwindle or are exhausted, terminally ill-patients often ... therapies. However, a team of researchers from Wake ... Medical Center and Unity Health System, report that ... governing end-of-life care may be leaving many medical ...
Cached Medicine News:Health News:A Thanksgiving Message From New York Blood Center 2Health News:A Thanksgiving Message From New York Blood Center 3Health News:WellPoint Announces Second Annual Innovation Event 2Health News:WellPoint Announces Second Annual Innovation Event 3Health News:HIV Vaccine Failure Still Brings Insights 2Health News:Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform 2Health News:Economic Stress Takes Toll on Health 2Health News:Doctors' questions about end-of-life legalities may result in patient pain 2Health News:Doctors' questions about end-of-life legalities may result in patient pain 3
For the quantitative in vitro determination of CK-MB in serum and plasma...
The ALT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alanine aminotransferase activity in serum or plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
... S-1™ Biodegradable Anteroir Cervical System, in conjunction ... with a collar), is intended for use ... fusion procedures as a means to maintain ... or autografts., This device is not intended ...
Medicine Products: